Evoke Pharma posts 47% Q2 sales gain but faces going-concern risk amid Eversana costs

Evoke Pharma, Inc. (NASDAQ: EVOK)

Snapshot - what's happening inside
- Company sells Gimoti® (metoclopramide) nasal spray; commercialized with Eversana since Oct 2020.
- Management reports product momentum: Q2 2025 net product sales rose to $3,752,142 (up 47% vs Q2 2024) and six‑month sales were $6,832,300 (up 59% vs H1 2024).
- Cash position: $12,059,072 as of June 30, 2025; management expects this plus future Gimoti sales to fund operations into Q3 2026 (absent accelerated repayment).
- Governance/structure: reverse stock split effective Aug 1, 2024; as of Aug 1, 2025 there were 1,558,465 shares outstanding.

Key financial facts (from Q2 / 6‑month 2025 filings)
- Net product sales (Q2): $3,752,142; (6 months): $6,832,300.
- Cost of goods sold (Q2): $167,679; (6 months): $209,292.
- Selling, general & administrative (Q2): $5,134,902; (6 months): $9,432,407.
- Research & development (Q2): $8,413; (6 months): $51,196.
- Loss from operations (Q2): $(1,558,852); (6 months): $(2,860,595).
- Net loss (Q2): $(1,570,976); (6 months): $(2,877,154).
- Net loss per share, basic & diluted (Q2): $(0.62); (6 months): $(1.13). Weighted‑average shares (Q2): 2,553,174; (6 months): 2,550,941.
- Cash used in operating activities (6 months): $(1,562,527).
- Total assets: $16,060,328; total liabilities: $11,685,836; total stockholders' equity: $4,374,492 (June 30, 2025).
- Current liabilities include note payable $5,000,000 and accrued interest payable $2,361,610 (both current as of June 30, 2025).
- Accounts receivable: $2,905,443; inventories: $641,872; prepaid expenses dropped to $288,572.

Positive items (income statement & operations)
- Revenue growth: clear top‑line improvement - Q2 revenue +47% YoY; H1 revenue +59% YoY.
- Gross margins look healthy: low COGS ($167,679 on $3.75M sales in Q2) - product margin remains favorable before heavy SG&A and profit‑share costs.
- Improving commercial traction metrics noted by management: 1,960 new inbound prescriptions in Q2 (up 9.3% vs prior quarter); refill rate ~70%; new prescribers +9% in the quarter.
- Stock‑based compensation reduced y/y for the six months ($188,637 in 2025 vs $380,607 in 2024), lowering non‑cash SG&A pressure.
- Cash balance of $12.06M provides a runway into mid‑2026 per management (subject to caveats below).

Negative items (income statement & risks)
- Heavy SG&A: $5.13M in Q2 and $9.43M YTD - SG&A growth (~38% YoY Q2) outpaces revenue growth in absolute dollars, driven largely by Eversana profit sharing and marketing.
- Eversana profit sharing is a major expense line: Q2 Eversana profit sharing recorded ~$3.19M; six months ~$5.81M - this materially depresses operating income.
- Recurring net losses: net loss $(1.57M) in Q2 and $(2.88M) YTD - the company remains unprofitable with ongoing negative cash flow from operations (used $(1.56M) in H1).
- Going concern: management discloses substantial doubt about ability to continue as a going concern beyond one year if financing or favorable events don't occur.
- Eversana relationship creates concentration and counterparty risk: unreimbursed commercialization costs to Eversana were approximately $79.8M as of June 30, 2025; Eversana holds a Net Profit Quarterly Termination Right (NPQTR) if net profits are negative for two consecutive quarters (which occurred); termination could accelerate repayment obligations (loan + accrued interest of $7.4M as of June 30, 2025) and require Evoke to build its own commercial infrastructure - a potentially large cash drain.
- Balance sheet pressure: current liabilities $11.62M vs cash $12.06M and equity $4.37M - limited cushion if unexpected liabilities or accelerated repayments occur.
- Dilution & warrant overhang: 1,853,047 warrants outstanding (various series), plus options - potential future dilution if exercised.

Operational & commercial context (concise)
- Management attributes sales growth to expanded pharmacy network (ASPN), better payer coverage and increased prescriber adoption. ASPN new inbound prescriptions Q2: ~1,960; refill conversion ~70%.
- Clinical/post‑marketing activity: company planning a single‑dose PK trial to support a lower dose strength; this will increase R&D and spend when run.
- Contract terms: Evoke retains >80% of net product profits (after reimbursing Eversana and other fixed costs) but must reimburse Eversana commercialization costs and profit share in the mid‑to‑high teens on net product profits; unreimbursed Eversana costs are large and payable under certain termination scenarios.

Key near‑term catalysts and risks to watch
- Catalyst: continued prescription momentum and higher fills converting to revenue could extend runway and validate commercial model.
- Risk: Eversana exercising NPQTR or otherwise terminating would likely accelerate the $7.4M loan repayment and require Evoke to assume commercial infrastructure costs - management flags this as a material going‑concern risk.
- Financing: company must access debt, equity, or strategic partnerships to fund operations beyond current runway - financing terms and timing are critical and could be dilutive.
- Clinical/regulatory: the planned PK post‑marketing trial timing and outcome could affect market access and label adjustments, and will consume cash.

Bottom line - straight talk
Evoke (NASDAQ: EVOK) is showing real commercial traction: sales growing rapidly from a low base and operational metrics improving (prescribers, fills, refills). But the business is still loss‑making with heavy SG&A driven by Eversana profit sharing and marketing, a meaningful note payable and $79.8M of unreimbursed Eversana costs that create a concentrated counterparty risk. Management's cash runway into Q3 2026 is conditional - an Eversana termination or slower sales growth would sharply shrink that cushion. Investors should weigh accelerating revenue and improving uptake against significant liquidity and partner‑termination risks.